Form 4: Relay Therapeutics Chief Legal Officer Acquires 275,000 Stock Options

Brian Adams, Chief Legal Officer of Relay Therapeutics, acquired 275,000 stock options on January 10, 2025, which vest quarterly over four years.

Summary

• Brian Adams, the Chief Legal Officer of Relay Therapeutics, acquired 275,000 stock options on January 10, 2025.
• The exercise price of these options is $4.45 per share.
• The options vest in 16 equal quarterly installments starting after January 10, 2025, contingent on continued service with the company.
• The options expire on January 9, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of stock options to a key executive like the Chief Legal Officer aligns his interests with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in the biotech industry.
• The vesting schedule of 16 equal quarterly installments is a typical approach to ensure long-term commitment.
• The exercise price of $4.45 is specific to Relay Therapeutics' stock and market conditions at the time of the grant.

Stakeholder Impact

• The stock option grant could positively impact shareholder value if the executive's performance contributes to the company's success.
• The vesting schedule encourages the executive's continued service, which benefits the company and its stakeholders.

Key Dates

Keywords

stock options, insider trading, executive compensation, Relay Therapeutics, RLAY, Brian Adams, Chief Legal Officer